Immunotech Biopharm Ltd (HKG:6978)
Hong Kong · Delayed Price · Currency is HKD 4.270
+0.070 (1.67%)
Aug 8, 2025, 4:08 PM HKT
Immunotech Biopharm Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Net Income | -186.91 | -334.82 | -318.11 | -354.22 | -439.05 | Upgrade |
Depreciation & Amortization | 59.3 | 52.22 | 43.11 | 20.82 | 13.74 | Upgrade |
Other Amortization | 1.58 | 1.18 | 14.46 | 0.19 | 0.04 | Upgrade |
Loss (Gain) From Sale of Assets | 0.04 | -0.2 | 0.64 | 0.09 | -0.08 | Upgrade |
Asset Writedown & Restructuring Costs | 0.56 | - | - | -1.3 | - | Upgrade |
Loss (Gain) From Sale of Investments | 19.81 | 90.01 | 24.02 | 18.79 | - | Upgrade |
Stock-Based Compensation | - | - | 4.29 | 48.95 | 151.7 | Upgrade |
Other Operating Activities | -41.84 | 15.67 | 5.59 | -7.04 | 39.32 | Upgrade |
Change in Inventory | -0.62 | 2.29 | 3.65 | -6.89 | 0.84 | Upgrade |
Change in Accounts Payable | -17.7 | 4.09 | 8.41 | 38.87 | 0.35 | Upgrade |
Change in Unearned Revenue | 0.56 | -0.71 | 3.29 | -0.35 | -2.1 | Upgrade |
Change in Other Net Operating Assets | 39.48 | 6.63 | 29.74 | -12.56 | -28.43 | Upgrade |
Operating Cash Flow | -125.74 | -163.63 | -180.92 | -254.65 | -263.67 | Upgrade |
Capital Expenditures | -27.26 | -19.58 | -68.15 | -146.01 | -25.04 | Upgrade |
Sale of Property, Plant & Equipment | 0.03 | 0.96 | 1.5 | 0.21 | 0.1 | Upgrade |
Sale (Purchase) of Intangibles | -0.81 | -2.96 | -7.55 | -22.32 | -0.49 | Upgrade |
Sale (Purchase) of Real Estate | - | - | -20.87 | -12.91 | -50.15 | Upgrade |
Investment in Securities | 140.83 | -100 | 78.06 | -150.09 | -131.97 | Upgrade |
Other Investing Activities | 28.31 | 4.99 | 40.39 | 2.91 | 3.48 | Upgrade |
Investing Cash Flow | 141.1 | -116.6 | 23.38 | -328.21 | -204.07 | Upgrade |
Long-Term Debt Issued | - | 300 | 1 | - | - | Upgrade |
Total Debt Issued | - | 300 | 1 | - | - | Upgrade |
Long-Term Debt Repaid | -13.1 | -17.56 | -17.43 | -7.32 | -4.48 | Upgrade |
Total Debt Repaid | -13.1 | -17.56 | -17.43 | -7.32 | -4.48 | Upgrade |
Net Debt Issued (Repaid) | -13.1 | 282.44 | -16.43 | -7.32 | -4.48 | Upgrade |
Issuance of Common Stock | - | - | - | - | 1,137 | Upgrade |
Other Financing Activities | -7.49 | -8.52 | -19.63 | -3.68 | -77.95 | Upgrade |
Financing Cash Flow | -20.59 | 273.92 | -36.06 | -11 | 1,055 | Upgrade |
Foreign Exchange Rate Adjustments | 0.02 | 0.02 | 0.65 | -0.13 | -23.82 | Upgrade |
Net Cash Flow | -5.2 | -6.29 | -192.95 | -593.99 | 563.14 | Upgrade |
Free Cash Flow | -153 | -183.21 | -249.07 | -400.67 | -288.7 | Upgrade |
Free Cash Flow Per Share | -0.30 | -0.36 | -0.48 | -0.78 | -0.65 | Upgrade |
Cash Interest Paid | 7.49 | 8.52 | 6.14 | 3.68 | 2.39 | Upgrade |
Cash Income Tax Paid | -0.04 | - | - | - | - | Upgrade |
Levered Free Cash Flow | -134.61 | -120.8 | -146.34 | -201.44 | -97.16 | Upgrade |
Unlevered Free Cash Flow | -129.93 | -115.47 | -156 | -199.15 | -95.67 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.